Investors Might Be Losing Patience for Merus' (NASDAQ:MRUS) Increasing Losses, as Stock Sheds 3.4% Over the Past Week

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well

Simply Wall StJul 21 08:57 ET

Institutional Investors Control 69% of Merus N.V. (NASDAQ:MRUS) and Were Rewarded Last Week After Stock Increased 5.5%

Yahoo FinanceJul 12 11:34 ET

Buy Rating Affirmed for Merus's Petosemtamab on Promising MCRC and HNSCC Trial Prospects

TipRanksJul 9 06:55 ET

Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate

Merus (MRUS) said Monday it has dosed first patient in its phase 2 trial of petosemtamab combined with standard chemotherapy to treat second-line metastatic colorectal cancer.The open-label trial aims

MT NewswiresJul 8 09:06 ET

Express News | Merus N.V. Doses First Patient In Phase 2 Trial Of Petosemtamab For Second-Line Metastatic Colorectal Cancer; Biclonics Therapy Targets EGFR And LGR5

BenzingaJul 8 08:01 ET

Express News | Merus NV - Phase 2 Trial to Enroll Approximately 40 Patients

ReutersJul 8 08:00 ET